DBV Technologies (NASDAQ:DBVT) Shares Gap Up – What’s Next?

DBV Technologies S.A. (NASDAQ:DBVT) shares gapped up before the market opened on Tuesday . The stock had previously closed at $14.14, but opened at $14.88. DBV Technologies shares last traded at $14.9430, with a volume of 20,999 shares trading hands.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on DBVT. Weiss Ratings lowered DBV Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, July 17th. Guggenheim reiterated a “buy” rating and issued a $51.00 price objective on shares of DBV Technologies in a research report on Monday, May 4th. Citigroup reaffirmed an “outperform” rating on shares of DBV Technologies in a research note on Friday, May 1st. HC Wainwright reaffirmed a “buy” rating on shares of DBV Technologies in a research note on Tuesday, June 30th. Finally, Wall Street Zen lowered DBV Technologies from a “hold” rating to a “sell” rating in a report on Saturday, July 4th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $48.50.

DBV Technologies Trading Up 5.5%

The stock has a fifty day moving average price of $14.94 and a 200 day moving average price of $18.35. The firm has a market cap of $937.86 million, a price-to-earnings ratio of -4.25 and a beta of -0.93.

DBV Technologies (NASDAQ:DBVT) last issued its quarterly earnings results on Thursday, July 16th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.48). The business had revenue of $0.70 million during the quarter, compared to analyst estimates of $0.90 million. DBV Technologies had a negative net margin of 3,506.53% and a negative return on equity of 119.33%. On average, sell-side analysts forecast that DBV Technologies S.A. will post -2.05 EPS for the current year.

Hedge Funds Weigh In On DBV Technologies

Several large investors have recently added to or reduced their stakes in DBVT. MPM Bioimpact LLC acquired a new position in shares of DBV Technologies in the 2nd quarter valued at $9,649,000. Adage Capital Partners GP L.L.C. bought a new stake in DBV Technologies during the 2nd quarter worth approximately $9,659,000. Octagon Capital Advisors LP bought a new stake in shares of DBV Technologies during the second quarter worth $9,315,000. Two Sigma Investments LP acquired a new stake in DBV Technologies in the 3rd quarter valued at about $167,000. Finally, Citadel Advisors LLC acquired a new stake in shares of DBV Technologies in the third quarter valued at approximately $220,000. Institutional investors and hedge funds own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.